Oct 13, 2021 / 08:30PM GMT
Operator
Thank you for standing by, and welcome to Xywav in IH launch. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)
I would now like to hand the conference over to your host, Andrea Flynn, Vice President of Investor Relations. Please go ahead.
Andrea N. Flynn - Jazz Pharmaceuticals plc - VP & Head of IR
Thank you. Good afternoon, everyone, and thank you for joining us today for a discussion on Xywav for idiopathic hypersomnia as we approach our commercial launch. The slide presentation accompanying this webcast is available on the Investors section of our website. Investors may also reference the press release we issued on August 12 regarding FDA approval of Xywav for the treatment of adults with IH.
On the webcast today are Bruce Cozadd, Chairman and Chief Executive Officer; Dr. Rob Iannone, Executive Vice President, R&D and Chief Medical Officer; and Kim Sablich, Executive Vice President and General Manager, North America.
We're pleased to have external sleep expert, Dr
Jazz Pharmaceuticals PLC Xywav Investor Update Transcript
Oct 14, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers